Recent Developments in Gene Targeted and Immunotherapies of Parkinson's Disease

MDS OnDemand Series


Available starting June 26, 2020

This accredited webinar is provided free of cost to all members and non-members.


Live Q&A Session
Wednesday, August 26 at 09:00 AM ET / 08:00 AM CT

Join Us Live

Presented by

Roy N. Alcalay, MD
Joseph Quinn, MD
Carlos Singer, MD

Course Description

The treatment of Parkinson’s disease (PD) has thus far been restricted to symptomatic therapies. These treatments improve quality of life but do not address PD’s relentless progression.

The discovery of genetic mutations that cause or increase the risk of development of PD has opened the possibility of genetically targeted therapies with the potential of slowing or stopping the progression of specific monogenetic forms of PD.  Further, the possibility that misfolded synuclein aggregation is a key pathogenetic factor in PD has culminated in ongoing trials of synuclein-targeted immunotherapies with a similar potential benefit for all forms of PD, be they genetic or sporadic.

This webinar will review the current state of affairs of clinical trials of both these types of therapies. The lectures will cover the pharmacology and recent results of relevant clinical trials, as well as their future directions.

Target Audience

This course is intended for neurologists interested or specializing in Movement Disorders.

Learning Objectives
  1. Describe the different mechanisms of action of the gene and synuclein targeted therapies of PD
  2. Explain the current state of development of clinical trials of both therapies
  3. Recognize the use of biomarkers to monitor target engagement and effect on progression of PD
  4. Identify future directions of these novel therapeutic modalities
Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The International Parkinson and Movement Disorder Society designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation.

Satisfactory Completion

Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.

Content Validity Statement

All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.

Faculty Financial Disclosure Information

All individuals in control of content for this webinar are required to disclose all relevant financial relationships with commercial interests as defined by the ACCME. Disclosure information is available here.


We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including and This cookie policy only covers the primary and domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice